Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Renal Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Renal Cancer
    Kidney Cancer Cryoablation Results in 9% Recurrence Rate After at Least 5 Years of Follow-Up: Presented at RSNA - (DGDispatch)
    Annual Report Finds Declines in Cancer Incidence and Death in US, But Wide Variation in Lung Cancer Trends - (DGNews)
    TopAbstracts in Renal Cancer 11/26/2008 - (DGNews)
    TopAbstracts in Renal Cancer 11/17/2008 - (DGNews)
    TopAbstracts in Renal Cancer 11/12/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Renal Cancer
    • Targeted Therapies Show Activity as First-Line Treatment of Renal Cell Carcinoma
    • Emerging Therapies and Combination Therapy as the Future of Renal Cell Carcinoma Treatment
    • Utilizing and Improving Prognostic Markers in Determining Best Treatment of Renal Cell Carcinoma
    • Targeted Agents Recommended for Renal Cell Carcinoma Therapy
    • New Science and Therapeutic Advances in the Treatment of Renal Cell Carcinoma: A Case Study Review

      Webcasts/CME archive

       Recent cases - Renal Cancer
        Oral Cavity Metastasis of Renal Cell Carcinoma: A Case Report
        Solitary Intrathyroidal Metastasis of Renal Clear Cell Carcinoma in a Toxic Substernal Multinodular Goiter
        Short-Term Effective Treatment of CNS Metastasis of Sarcomatoid Renal Cell Carcinoma with Temozolomide and Pegylated Liposomal Doxorubicin: A Case Report
        Primitive Neuroectodermal Tumour of the Kidney with Vena Caval and Atrial Tumour Thrombus: A Case Report
        Tongue Metastasis as an Initial Presentation of Renal Cell Carcinoma: A Case Report and Literature Review

        Cases archive
          




        my personal edition > renal cancer > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Sunitinib (Sutent) Improves Quality of Life Over Interferon-Alfa in Kidney Cancer: Presented at ICACT

        By Jill Stein

        PARIS, FRANCE -- February 8, 2007 -- Sunitinib malate (Sutent) produces larger improvements in quality of life than interferon-alfa in patients with metastatic renal cell carcinoma, investigators reported here at the 18th International Congress on Anti-Cancer Treatment (ICACT).

        Joseph C. Cappelleri, PhD, director, biostatistics division, Global Research and Development, Pfizer Inc, Groton, Connecticut, presented the results of quality of life analyses from a recent phase 3 trial in a presentation on February 8th.

        In a previous analysis of data from this study, researchers found that sunitinib was associated with significantly increased progression-free survival compared with interferon-alfa in patients with metastatic renal cell carcinoma (N Engl J Med 2007;356(2):115-124).

        In the present quality of life analysis, the researchers used both repeated measures mixed-effects models (MEM) and pattern-mixture models (PMM) to test the robustness of treatment effect on health-related quality of life (HRQoL).

        The study included 750 patients who were randomized to treatment with either sunitinib in repeated 6-week cycles of 50 mg/day administered orally for 4 weeks followed by 2 weeks off treatment or subcutaneous interferon-alfa 3 times weekly on non-consecutive days at 3 MU per dose during the first week, 6 MU per dose the second week, and 9 MU per dose thereafter.

        Quality of life was measured by the Functional Assessment of Cancer Therapy - General and Kidney Symptom Index, and with the EuroQol Group's EQ-5D self-report questionnaire. Higher scores denoted better outcomes for all endpoints. Patients completed questionnaires on days 1 and 28 of each cycle. Data were analyzed for up to 9 cycles of sunitinib treatment.

        For all HRQoL endpoints, the overall post-randomization least-square means estimated by MEM favored sunitinib (all P <.01).

        Also, the results from the PMM were generally consistent with the results from the repeated measures MEM.

        "Overall, the results demonstrate that sunitinib outperforms alfa-interferon in providing important quality of life improvements in metastatic renal cell carcinoma," Dr. Cappelleri commented. "This is important because it means that sunitinib confers benefit beyond an improved progression-free survival."

        Sunitinib malate is an oral, multi-targeted receptor tyrosine kinase inhibitor with both anti-tumor and anti-angiogenic effects.

        Sunitinib has shown activity against a variety of tumors and has been approved in several countries for the treatment of imatinib-resistant or -intolerant gastrointestinal stromal tumors and for advanced and/or metastatic renal cell carcinoma.

        The study was sponsored by Pfizer.


        [Presentation title: Effects of Sunitinib Versus Interferon Alfa on Health-Related Quality of Life in Patients with Metastatic Renal Cell Carcinoma: Comparing the Results of Mixed-Effects and Pattern-Mixture Models. Abstract Number 325]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send